雷珠单抗玻璃体内注射治疗白内障术后顽固性囊样黄斑水肿的效果

The effect of intravitreal Ranibizumab for refractory cystoid macular edema after cataract surgery

目的评价雷珠单抗（Ranibizumab）玻璃体内注射治疗常规老年性白内障术后人工晶状体眼顽固性囊样黄斑水肿的效果。 方法此类顽固性囊样黄斑水肿接受雷珠单抗玻璃体内注射治疗5例，随访3～6个月。对比治疗前后视力、黄斑部视网膜形态及厚度。 结果经1次治疗后，视力均明显提高，黄斑部视网膜水肿消失，无水肿复发，无并发症发生。 结论雷珠单抗治疗常规老年性白内障术后顽固性囊样黄斑水肿是安全而有效的。

Objective To evaluate the effect of intravitreal Ranibizumab for refractory pseudophakic cystoid maeular edema （CME） after routine senile cataract surgery. Methods From April 2013 to May 2015, 5 patients with refractory pseudophakic CME were treated with intravitreal Ranibizumab injection. Followed up for 3 - 6 months, visual acuity, retinal morpho!ogy and thickness of macula were compared before and after treatment to evaluate the effect. Results After once treatment of intravitreal Ranibizumab, all patients showed better visual acuity and less macular edema without recurrence or complication. Conclusion Intravitreal Ranibizumab is safe and effective for refractory pseudophakic cystoid macular edema